Globus Medical Q1 EPS Estimate Increased by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research increased their Q1 2026 earnings per share estimates for Globus Medical in a research note issued on Tuesday, March 10th. Zacks Research analyst Team now expects that the medical device company will post earnings of $0.88 per share for the quarter, up from their prior estimate of $0.80. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q2 2026 earnings at $1.02 EPS, Q3 2026 earnings at $1.13 EPS, Q4 2027 earnings at $1.23 EPS and FY2028 earnings at $5.18 EPS.

Other equities research analysts have also issued reports about the stock. Citigroup reaffirmed a “market perform” rating on shares of Globus Medical in a report on Thursday, January 8th. Canaccord Genuity Group lifted their target price on shares of Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Wall Street Zen upgraded Globus Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 3rd. Wells Fargo & Company upped their price target on Globus Medical from $98.00 to $104.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Globus Medical in a research report on Tuesday, December 30th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.36.

Globus Medical Price Performance

NYSE GMED opened at $86.61 on Wednesday. The stock’s fifty day moving average price is $90.82 and its 200 day moving average price is $77.99. Globus Medical has a 1 year low of $51.79 and a 1 year high of $101.40. The company has a market cap of $11.71 billion, a price-to-earnings ratio of 21.98, a PEG ratio of 2.05 and a beta of 1.05.

Globus Medical (NYSE:GMED) last released its earnings results on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. The company had revenue of $826.42 million during the quarter, compared to analysts’ expectations of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. Globus Medical’s revenue for the quarter was up 25.7% on a year-over-year basis. During the same period last year, the business earned $0.84 EPS.

Insider Buying and Selling

In other Globus Medical news, Director Leslie V. Norwalk sold 2,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the sale, the director directly owned 10,419 shares of the company’s stock, valued at approximately $1,053,360.90. This trade represents a 16.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kyle Kline sold 3,594 shares of the stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $363,353.40. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 35,594 shares of company stock worth $3,332,253 in the last 90 days. Company insiders own 18.54% of the company’s stock.

Institutional Trading of Globus Medical

Institutional investors have recently modified their holdings of the company. SBI Securities Co. Ltd. boosted its holdings in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the period. Advisory Services Network LLC bought a new position in shares of Globus Medical during the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC lifted its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in shares of Globus Medical during the second quarter valued at approximately $28,000. Finally, Larson Financial Group LLC raised its stake in shares of Globus Medical by 83.4% during the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 242 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised near-term and longer-term EPS estimates (Q1–Q4/FY2028) and carries a “Strong‑Buy” view, reflecting upward revision to Q1–Q3/Q4 forecasts and a FY2028 projection of $5.18 — a clear analyst tailwind for GMED.
• Positive Sentiment: Globus reported a solid Q4 beat earlier this year (EPS $1.28 vs. $1.06 estimate; revenue ~$826M, +25.7% YoY), demonstrating revenue growth and margin leverage that support valuation over time.
• Positive Sentiment: Short interest fell sharply (~30% drop in February to ~3.27M shares, ~3.0% of float), reducing the pool of bearish bets and the potential for short‑squeeze volatility.
• Neutral Sentiment: Technical and idea pieces highlight GMED as a buy on short‑term setups (hammer pattern/analyst list of medical-instrument picks), which may attract tactical buyers but doesn’t guarantee near-term price direction. Bears are Losing Control Over Globus Medical (GMED), Here’s Why It’s a ‘Buy’ Now
• Neutral Sentiment: Zacks and other analysts continue to feature GMED in thematic lists (medical instruments/AI & product pipeline tailwinds), which supports investor interest but is a longer‑horizon constructive signal. 5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
• Neutral Sentiment: Management has reaffirmed its 2026 outlook; analysts are parsing that guidance to assess capital-allocation priorities (share repurchases, M&A, or reinvestment), so near‑term impact is uncertain. Does Globus Medical’s (GMED) Reaffirmed 2026 Outlook Reveal Its Next Capital Allocation Priorities?
• Negative Sentiment: Recent commentary and fair‑value assessments have flagged share‑price weakness and potential valuation pressure after earlier gains, which likely contributed to selling/profit‑taking today. Assessing Globus Medical (GMED) After Recent Share Price Weakness And Fair Value Signals
• Negative Sentiment: With lower short interest and fewer forced buybacks from short covering, there is less mechanical upside from short‑covering moves, which can mute rebounds after pullbacks.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.